AcouSort AB (ACOU) AI Stock Analysis

• Market Cap: kr62.01M
• Dividend Yield: N/A
• Average Volume (3M): 29.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.37
• Revenue Growth: 59.70%
• EPS Growth: 44.60%
• Country: SE
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.12
• Shares Outstanding: 21,163,902
• 10 Day Avg. Volume: 27,764
• 30 Day Avg. Volume: 29,240
• PEG Ratio: 0.12
• Price to Book (P/B): 3.27
• Price to Sales (P/S): 7.79
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.4
• Revenue Forecast (FY): kr18.80M

• Rating: 52 Neutral
• Price Target: kr3.00 ▲(13.64% Upside)
• Action: Reiterated Date: 03/12/26
• Date: Action: Reiterated 03/12/26

The score is held back primarily by weak financial performance driven by ongoing losses and negative operating cash flow, despite a low-leverage balance sheet (no reported debt). Technicals are modestly supportive with the stock trading above key shorter-term averages, while valuation remains challenged by negative earnings and no dividend yield provided.

Positive Factors

Low Leverage

Zero reported debt materially reduces refinancing and interest-rate risk and strengthens solvency. For a cash-burning medtech developer, low leverage provides durable runway flexibility to prioritize R&D, partnerships, or targeted commercial investments without near-term debt pressure.

Recovering Revenue

A clear year-over-year revenue pickup signals improving product demand or commercial traction for the AcouWash platform. Sustained top-line growth supports scale benefits, potential higher utilization in bioprocessing customers, and a pathway to margin improvement if the trend persists.

Differentiated Platform Tech

AcouWash is a niche, label-free acoustofluidic separation platform targeting cell therapy and bioprocessing—areas with structural growth. Technology differentiation and integration into manufacturing workflows can create durable competitive advantage and recurring demand from process-critical customers.

Negative Factors

Negative Operating Cash Flow

Sustained negative operating cash flow means core operations do not self-fund, creating ongoing dependency on external financing. Over the medium term this raises funding risk, can force dilutive equity raises, and limits the firm’s ability to invest consistently in commercialization and scale-up.

Persistent Losses

Chronic unprofitability and repeated operating losses indicate the business has not yet achieved sustainable unit economics. This undermines free-cash-flow conversion potential and means the company must demonstrate structural margin improvement to become self-sustaining over the medium term.

Reliance on Equity Funding

Variable equity levels point to recurring capital raises as the primary funding source. That reliance increases shareholder dilution risk, creates uncertainty about long-term capital availability, and can constrain strategic choices if financing terms or timing are adverse.

AcouSort AB Business Overview & Revenue Model

Company Description

AcouSort AB (publ), a technology company, develops products and solutions for automated preparation of biological samples based on acoustofluidics technology for researchers and life science companies. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an integrated blood plasma separation module that enables in-line analysis of blood plasma from whole blood samples; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company was founded in 2010 and is based in Lund, Sweden.

How the Company Makes Money

null

AcouSort AB Financial Statement Overview

Summary

Financials are constrained by sustained losses and cash burn (negative net income and EBIT/EBITDA across 2020–2025; operating cash flow negative in 2023–2025). This is partially offset by a stronger balance sheet profile with zero reported debt and positive equity, reducing near-term financial risk.

Income Statement

Revenue has been volatile but improved in 2025 (+22% year over year) after a weaker 2024, which is a positive sign for demand. However, profitability remains very weak: the company has reported losses every year (net income negative across 2020–2025), and operating results are deeply negative (EBIT and EBITDA losses each year). Margins are consistently negative at the bottom line, and 2025 also shows a sharply negative gross margin, indicating cost pressure and/or one-offs that overwhelmed revenue.

Balance Sheet

The balance sheet is a relative strength: total debt is reported as zero across all periods, which materially reduces financial risk and refinancing pressure. Equity is positive each year, supporting solvency, but returns to shareholders are poor with consistently negative return on equity driven by ongoing losses. Equity levels also fluctuate significantly year-to-year, suggesting the company may be relying on equity funding to sustain operations.

Cash Flow

Cash generation is weak and inconsistent. Operating cash flow is negative in most years (notably 2023–2025), indicating the core business is not self-funding, and free cash flow is negative in multiple periods as well. While 2022 showed positive operating and free cash flow, the subsequent deterioration (large cash outflows in 2023–2025) raises funding risk and points to continued dependence on external capital if the trend persists.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.85M	4.74M	10.55M	4.96M	3.01M
Gross Profit	-14.50M	4.77M	8.39M	2.91M	548.00K
EBITDA	-14.33M	-15.89M	-16.70M	-12.86M	-11.46M
Net Income	-12.15M	-15.08M	-17.09M	-13.21M	-12.38M
Balance Sheet
Total Assets	17.89M	12.32M	34.51M	42.66M	36.56M
Cash, Cash Equivalents and Short-Term Investments	6.29M	3.57M	23.99M	33.97M	31.52M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	1.59M	3.86M	10.38M	22.54M	3.54M
Stockholders Equity	16.30M	8.46M	24.14M	20.11M	33.02M
Cash Flow
Free Cash Flow	0.00	-19.84M	-31.77M	2.95M	-12.23M
Operating Cash Flow	-16.78M	-18.81M	-31.56M	3.96M	-10.92M
Investing Cash Flow	-488.00K	-1.02M	-1.16M	-1.01M	-1.31M
Financing Cash Flow	18.98M	-157.00K	22.08M	0.00	35.63M

AcouSort AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.64
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACOU, the sentiment is Positive. The current price of 2.64 is above the 20-day moving average (MA) of 2.58, above the 50-day MA of 2.63, and below the 200-day MA of 2.98, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 62.51 is Neutral, neither overbought nor oversold. The STOCH value of 72.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ACOU.

AcouSort AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SPRINT	79 Outperform	kr215.25M	1.48	-264.12%	―	-17.80%	-11.96%
ACOU	52 Neutral	kr62.01M	-4.39	-79.59%	―	59.70%	44.60%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ONCOZ	47 Neutral	kr81.06M	-5.14	-202.18%	―	―	20.55%
PILA	44 Neutral	kr53.54M	―	-601.02%	―	―	―
EXPRS2	43 Neutral	kr18.25M	-1.19	-88.65%	―	8.46%	11.73%
LARK	43 Neutral	kr40.99M	-1.97	―	8.47%	-94.12%	-25.83%